CDKN2A and thyroid cancer: A pan-cancer survival analysis revealed that CDKN2A-ALT patients had a shorter OS than CDKN2A-WT patients in 23 cancer types, including thymic epithelial tumor, thyroid cancer, renal non clear cell carcinoma, salivary gland cancer, gastrointestinal stromal tumor, adrenocortical carcinoma and so on.